Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment
AIDS, Volume 27, No. 6, Year 2013
Notification
URL copied to clipboard!
Description
Objective: To investigate the pharmacokinetics of artemether, dihydroartemisinin and lumefantrine during rifampicin intake and after stopping rifampicin. Study design: An open-label, two-phase, longitudinal drug interaction study with patients serving as their own controls. Methods: We recruited HIV-1-seropositive Ugandan adults who were receiving rifampicin- based tuberculosis treatment and who did not have malaria. Pharmacokinetic sampling after six doses of artemether-lumefantrine was performed during rifampicinbased tuberculosis treatment (phase 1) and repeated at least 3 weeks after stopping rifampicin-based tuberculosis treatment (phase 2). Results: Six and five patients completed phases 1 and 2, respectively. Median age and weight were 30 years and 64 kg. Artemether and dihydroartemisinin area under the concentration-time curve (AUC0-12h) were significantly lower by 89% [geometric mean ratio (GMR) 90% confidence interval (CI) 0.11, 0.05-0.26] and 85% (0.15, 0.10-0.23), respectively, during rifampicin-based treatment when compared to AUC0-12h after stopping rifampicin intake. Similarly, artemether and dihydroartemisinin Cmax were 83% (0.17, 0.08-0.39) and 78% (0.22, 0.15-0.33) lower, respectively, during rifampicin treatment. For artemether, mean (±SD) C12 was 0.5(±1.0) and 5.9(±2.5) ng/ml in phases 1 and 2, respectively. Corresponding values for dihydroartemisinin (DHA) were 0.3(±0.4) and 4.7(±2.0) ng/ml, respectively. Day 8 lumefantrine concentration was significantly lower by 84% (GMR 90% CI 0.16, 0.09-0.27), and AUCDay3-Day25 was significantly lower by 68% (GMR 90% CI 0.32, 0.21-0.49) during rifampicin-based treatment when compared to exposure values after stopping rifampicin. © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Authors & Co-Authors
Lamorde, Mohammed
Uganda, Kampala
Makerere University
Ireland, Dublin
Trinity College Dublin
Byakika-Kibwika, Pauline
Uganda, Kampala
Makerere University
Ireland, Dublin
Trinity College Dublin
Uganda, Kampala
Infectious Diseases Network for Treatment and Research in Africa
Mayito, Jonathan
Uganda, Kampala
Makerere University
Nabukeera, Lillian
Uganda, Kampala
Makerere University
Ryan, Máirín A.A.
Ireland, Dublin
Trinity College Dublin
Hanpithakpong, Warunee
Thailand, Bangkok
Mahidol Oxford Tropical Medicine Research Unit
Lefèvre, Gilbert
Switzerland, Basel
Novartis International ag
Back, David J.
United Kingdom, Liverpool
University of Liverpool
Khoo, Saye Hock
United Kingdom, Liverpool
University of Liverpool
Merry, Concepta
Uganda, Kampala
Makerere University
Ireland, Dublin
Trinity College Dublin
Ireland, Dublin
St James's Hospital
Statistics
Citations: 26
Authors: 10
Affiliations: 7
Identifiers
Doi:
10.1097/QAD.0b013e32835cae3b
e-ISSN:
14735571
Research Areas
Infectious Diseases
Study Design
Cohort Study